Moreover, in a subanalysis of the LIPID trial, the addition of BNP to five other biomarkers included in a clinical risk model significantly improved the prediction of five-year HF occurrence in patients who experienced an ACS 3–36 months prior to randomization [15]. Here, NPPB is linked to hydrops fetalis.